Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
The Journal of Cell Biology
|
May 16, 2019
Respiratory chain inactivation links cartilage-mediated growth retardation to mitochondrial diseases
Tatjana Holzer, Kristina Probst, Julia Etich, et al.
Pharmacogenomics
|
May 7, 2015
CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study
Kristina Probst-Schendzielorz, Catharina Scholl, Olga Efimkina, et al.
Journal of Neuromuscular Diseases
|
September 12, 2025
Phenotypic intrafamilial variability of 5q-associated spinal muscular atrophy: A systematic multicentre sibling study
Benedikt Becker, Isabell Cordts, Jutta Becker, et al.
JAMA Pediatrics
|
April 8, 2024
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial
Oliver Schwartz, Katharina Vill, Michelle Pfaffenlehner, et al.
Journal of Neurology
|
February 27, 2024
5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2
Katharina Vill, Moritz Tacke, Anna König, et al.
The Lancet Regional Health. Europe
|
February 16, 2024
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
René Günther, Claudia Diana Wurster, Svenja Brakemeier, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
The Journal of Cell Biology
|
May 16, 2019
Respiratory chain inactivation links cartilage-mediated growth retardation to mitochondrial diseases
Tatjana Holzer, Kristina Probst, Julia Etich, et al.
Pharmacogenomics
|
May 7, 2015
CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study
Kristina Probst-Schendzielorz, Catharina Scholl, Olga Efimkina, et al.
Journal of Neuromuscular Diseases
|
September 12, 2025
Phenotypic intrafamilial variability of 5q-associated spinal muscular atrophy: A systematic multicentre sibling study
Benedikt Becker, Isabell Cordts, Jutta Becker, et al.
JAMA Pediatrics
|
April 8, 2024
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial
Oliver Schwartz, Katharina Vill, Michelle Pfaffenlehner, et al.
Journal of Neurology
|
February 27, 2024
5qSMA: standardised retrospective natural history assessment in 268 patients with four copies of SMN2
Katharina Vill, Moritz Tacke, Anna König, et al.
The Lancet Regional Health. Europe
|
February 16, 2024
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
René Günther, Claudia Diana Wurster, Svenja Brakemeier, et al.
Page
of 2